eBulletin Newsletter

NCCN Flash Updates: NCCN Guidelines Updated for Kidney Cancer

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™) for Kidney Cancer. These NCCN Guidelines^® are currently available as Version 2.2023.

Link directly to the Updates section of the NCCN Guidelines: Kidney Cancer

Updates in Version 2.2023 of the NCCN Guidelines for Kidney Cancer from Version 1.2023 include:

KID-B (1 of 5)

• Follow-up
  • Stage 1 (T1a)
    • Follow-up During Active Surveillance
      • Bullet 4, sub-bullet 2 added: Consider repeat chest imaging if intervention is being contemplated.
    • Follow-up After Ablative Techniques
      • Bullet 3, sub-bullet 1 revised: "Abdominal CT or MRI with and without IV contrast (unless otherwise contraindicated) at 1–6 mo following ablative therapy unless otherwise contraindicated, then CT or MRI (preferred), or US annually for 5 y or longer as clinically indicated..."
      • Bullet 4, sub-bullet 1 revised: Chest x-ray or CT annually for 5 y for patients who have biopsy-proven low-risk pathologic features (no sarcomatoid, low-grade [grade 1/2]) renal cell carcinoma (RCC), nondiagnostic biopsies, or no prior biopsy

KID-B (2 of 5)

• Follow-up
  • Stage 1
    • Follow-up After a Partial or Radical Nephrectomy
      • Bullet 4, sub-bullet 1 revised: Baseline abdominal CT or MRI (preferred), or US within 3–12 mo of surgery, then annually for up to 5y or longer as clinically indicated.
      • Bullet 4, sub-bullet 2 revised: "A more rigorous imaging schedule or technique modality can be considered..."
  • Stage II
    • New section added: Follow-up After a Partial or Radical Nephrectomy

KID-B (3 of 5)

• Follow-up
  • Heading revised: Follow-up for Stage II or III

KID-B (4 of 5)

• Follow-up
  • Follow-up After Adjuvant Therapy
    • Bullet 1 revised: Patients who received adjuvant therapy should receive clinical follow-up as for stage II or III disease.

KID-B (5 of 5)

• Follow-up
  • Long-term Follow-Up (>5 y)
    • Bullet 3 revised: H&P should be performed annually to evaluate development of metastatic disease or sequelae of treatment.

Previous updates to the NCCN Guidelines for Kidney Cancer can be found in the UPDATES section of the current version.

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium^®), the NCCN Biomarkers Compendium^®, the NCCN Chemotherapy Order Templates (NCCN Templates^®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.

To view the NCCN Guidelines for Patients^®, please visit NCCN.org/patientguidelines.

Free NCCN Guidelines apps for iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps.

About NCCN Flash Updates™

NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium^®, and other NCCN Content.

Subscribe to NCCN Flash Updates™

Please note: 1. Third Party Content. The NCCN Content may contain content (such as figures, tables or illustrations) that NCCN licenses from third parties as displayed on NCCN Third Party Content FTP site: ftp://ftp1.nccn.org (To access: user name:content; password is NCCNcontent) (“Third Party Content”). Licensee shall be solely responsible for obtaining permissions from each such third party to use any such Third Party Content in the Permitted Works.

Access information on permissions and licensing of NCCN Content

Users may unsubscribe from Flash Updates at any time by contacting us. NOTE: The subscription fee for NCCN Flash Updates™ is non-refundable.